Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Elizabeth Gardner

Latest:

Older Breast Cancer Patients Require Special Consideration

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

Elizabeth Garner, MD, MPH

Latest:

Dr. Garner Discusses the myRisk Hereditary Cancer Test

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Elizabeth H. Baldini, MD, MPH

Latest:

Dr. Elizabeth H. Baldini on Systemic Therapy for Sarcoma

Elizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma

Elizabeth J. Shpall, MD

Latest:

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Elizabeth Leick

Latest:

Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Elizabeth M. Gore, MD

Latest:

Dr. Gore on Toxicity in Elderly Lung Cancer Patients

Dr. Elizabeth Gore, from the Medical College of Wisconsin, on Toxicity in Elderly Lung Cancer Patients

Elizabeth M. Swisher, MD

Latest:

Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian Cancer

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

Elizabeth Mittendorf Dana-Farber

Elizabeth Mittendorf, MD

Latest:

Dr. Mittendorf on Vaccines as Prevention for Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the possibility of using vaccines as a preventative measure for breast cancer, particularly to fight recurrence.

Elizabeth Mittendorf, MD, PhD, MHCM

Elizabeth Mittendorf, MD, PhD, MHCM, is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and the vice chair for research in the Department of Surgery at the Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School

Latest:

Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Elizabeth Petri Henske, MD

Latest:

Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.